Myto Therapeutics develops novel small-molecules that ameliorate orphan mitochondrial diseases, including Friedreich's ataxia and Leigh Syndrome. Our patented technology delivers bioactive monomethyl fumarate molecules with superior pharmacokinetics (PK) to other marketed prodrugs. The superior PK of our molecules underlies their greater pharmacodynamic potency to ameliorate mitochondrial diseases. The Mechanism of Action of our MYT-109 suggests it is a 'platform' drug, which could treat multiple mitochondrial diseases.
Company Details
- Employees
- 2
- Founded
- -
- Address
- Davis, Ca, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.mytothera.com
- HQ
- Davis, CA
Myto Therapeutics Questions
Myto Therapeutics's website is http://www.mytothera.com
Myto Therapeutics's LinkedIn profile is https://www.linkedin.com/company/mytotx
Myto Therapeutics has
2 employees.
View email and phone details for 2
employees at Myto Therapeutics.
Myto Therapeutics's industry is
Biotechnology Research
Myto Therapeutics's top competitors are
Ecfx,
Cyro Healthcare Pvt. Ltd.,
Aim Biotech,
Lifespace Labs,
Myto Ai,
Wuxi Biologics,
Sphaera Pharma.
Myto Therapeutics's categories are Biotechnology Research
Myto Therapeutics's founding year is 2021
